May 1, 2014 – EST
Most of the CHO-base transient gene expression (TGE) systems are based on engineered CHO cells, unique expression constructs, or specialized regents. These systems, as well highly optimized protocols for lipids and polyethylenimine (PEI), have varying levels of reproducibility, scalability, and cost effectiveness, and in general produce antibody titers from 10 to 100 mg/L for typical IgG. They have an even lower expression levels for difficult-to-express cells.
The MaxCyte flow electroporation platform provides a universal means of fully scalable, highly efficient transient transfection for rapid high titer antibody production in CHO cells, often >1 gram/Liter with optimization. All without the use of specialized reagents, expression vectors, or engineered CHO cell lines. Having adequate quantities of antibodies earlier for characterization and proof of concept studies can accelerate and improve candidate selection. Additionally, the platform can also be used to produce other proteins and works with a variety of other cell types like HEK, Vero, CAP-T®, insect cells, primary cells, stem cells, and other difficult-to-transfect cells. The same technology can also generate transfected cells with high viability and transfection efficiency for stable pools and for the selection and rapid generation of high yield stable clones, thus bridging the gap between early and late stage antibody development activities.
- Gain a familiarity with scalable flow transfection
- Learn how to generate large quantities of protein quickly
- Discover how to accelerate product development
- Understand the difference between electroporation as a consistent, reproducible transfection method compared with chemical methods
- Learn how to rapidly obtain high expression with difficult-to-express proteins
|James Brady, Ph.D., MBA.
Director of Technical Applications
|Jérôme Courtête, Ph.D.,
Head of Protein Production and Purification Group
Valneva, Inc. (formerly known as Vivalis)